e-ISSN: 0976-822X, p-ISSN:2961-6042

Available online on http://www.ijcpr.com/

International Journal of Current Pharmaceutical Review and Research 2025; 17(9); 886-890

Original Research Article

Impact of Lifestyle Interventions versus Pharmacological Therapy on Glycemic Control and Metabolic Parameters in Type 2 Diabetes

Kunjal Bhanubhai Finaviya[1], Parthik Bipinbhai Mehta[2], Yash Rajeshbhai Bhut[3]

[1]MBBS Intern, GMERS Medical College and Hospital, Valsad, Gujarat, India
[2]Medical Officer (MBBS), GMERS Medical College and Hospital, Valsad, Gujarat, India
[3]Medical Officer (MBBS), GMERS Medical College and Hospital, Valsad, Gujarat, India

Received: 21-07-2025 / Revised: 20-08-2025 / Accepted: 21-09-2025
Corresponding Author: Yash Rajeshbhai Bhut
Conflict of interest: Nil

Abstract:

Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease marked by hyperglycemia resulting from insulin resistance and evolving β-cell failure. It is present in more than 537 million adults worldwide and makes a significant contribution to morbidity and mortality via cardiovascular disease, nephropathy, neuropathy, and retinopathy. Pharmacological management effectively reduces blood glucose levels, but the drawbacks of long-term use include side effects, expense, and poor compliance. Lifestyle treatments, including diet modification, exercise, and behavioral therapy, have become an essential method for enhancing glycemic control and metabolic factors.

Objectives: The present study aimed to evaluate the effectiveness of intensive lifestyle treatment compared with standard pharmacological treatment in terms of glycemic control, lipid levels, body weight, and other metabolic markers in individuals with type 2 diabetes mellitus (T2DM), to determine which method offers greater or additive benefits for long-term metabolic well-being.

Materials and Methods: A prospective, interventional, comparative study was conducted at a tertiary care center over one year in 183 adult T2DM patients between the ages of 30 and 65 years. Participants were randomly assigned to either a lifestyle intervention group (structured diet, exercise, and counseling) or a pharmacological therapy group (routine anti-diabetic medications). Baseline and follow-up assessments were conducted using measurements of HbA1c, fasting blood glucose, lipid profile, body weight, BMI, and blood pressure. Data were evaluated using descriptive and inferential statistics, and $p < 0.05$ was used as significance.

Results: Lifestyle treatment resulted in more significant improvement in glycemic control (reduction in HbA1c: 1.8% vs. 1.2%; reduction in fasting glucose: 35 mg/dl vs. 25 mg/dl), body weight (4.5 kg vs. 1.0 kg), BMI (1.6 kg/m² vs. 0.4 kg/m²), and lipid profile (larger decrease in total cholesterol, LDL, triglycerides, and larger increase in HDL) than pharmacological treatment.

Conclusion: Structured lifestyle interventions are superior to pharmacological therapy alone in improving glycemic control and metabolic parameters in patients with type 2 diabetes mellitus (T2DM). The combination of lifestyle changes with pharmacotherapy may offer an optimal strategy for lowering cardiovascular risk and long-term metabolic well-being.

Keywords: Carry-over Effects, Type 2 Diabetes Mellitus, Lifestyle Intervention, Pharmacological Therapy, Glycemic Control, Lipid Profile, Metabolic Parameters, Body Weight.

Introduction

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by chronic hyperglycemia resulting from both insulin resistance and declining pancreatic β-cell function. Worldwide, T2DM has become epidemic in prevalence, with over 537 million adults affected and contributing substantially to morbidity and mortality through its link to cardiovascular disease, nephropathy, neuropathy, and retinopathy [1]. The treatment of T2DM is multifaceted and involves complex interventions that not only reduce blood glucose levels but also enhance the overall metabolic status of an individual, such as lipid profiles, blood pressure, and body weight [2]. The mainstay of treatment for T2DM has been pharmacological treatment, with drugs such as metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and insulin being commonly used. These drugs are very effective in lowering hyperglycemia but tend to be accompanied by adverse effects, are expensive, and difficult when it comes to long-term compliance [3].

Over the last several decades, lifestyle interventions—encompassing dietary changes, organized physical activity, behavioral counseling, and weight control—have emerged as primary interventions in the prevention and treatment of type 2 diabetes mellitus (T2DM) [4]. Lifestyle interventions have been shown to improve not only glycemic control but also body weight, insulin sensitivity, lipid metabolism, and cardiovascular risk factors [5]. In contrast to pharmacologic agents, lifestyle modifications address the core pathophysiology of T2DM, focusing on the importance of energy balance, food quality, and exercise in sustaining metabolic homeostasis. In addition, lifestyle changes may decrease or postpone the necessity for pharmacotherapy, thus reducing drug-associated side effects and enhancing overall well-being [6].

Despite the proven advantages of both pharmacological treatment and lifestyle interventions, head-to-head comparative studies to determine their relative effectiveness in glycemic control and overall metabolic effects are scarce [7]. There is a need to understand the differential impact of these approaches to optimize personalized treatment strategies for T2DM patients. This research will compare the efficacy of lifestyle modification with conventional pharmacologic therapy in enhancing glycemic control, insulin sensitivity, lipid profiles, and other metabolic parameters among patients with type 2 diabetes [8]. By comparing these outcomes, the study will generate evidence-based conclusions that can inform clinical decision-making, enhance patient compliance, and guide the integration of lifestyle modifications into comprehensive diabetes management programs [9].

This research aims to assess and compare the effectiveness of organized lifestyle interventions and conventional pharmacological therapy on metabolic parameters and glycemic control in patients with type 2 diabetes mellitus, to determine which strategy provides superior or additive benefits in maximizing long-term metabolic well-being.

Methodology

Study Design: This will be a prospective, comparative, interventional trial designed to assess the impact of lifestyle interventions versus pharmacological therapy on glycemic control and metabolic profile in patients with type 2 diabetes mellitus (T2DM).

Study Setting: The study will be conducted at a tertiary care center, utilizing both outpatient and inpatient departments for recruitment, follow-up, and monitoring of the subjects.

Study Population - The study population will comprise adult T2DM patients aged between 30 and 65 years who present at the hospital for diabetes management or as new cases requiring intervention.

Study Duration: The study process will span over a period of 1 year, encompassing recruitment, intervention, and follow-up.

Sample Size: 183 participants will be recruited for the study, as calculated based on prevalence data, anticipated effect size, and tolerable margin of error to ensure sufficient statistical power.

Inclusion Criteria: Individuals between 30 and 65 years old with documented type 2 diabetes mellitus (T2DM), a 7–10% HbA1c level, and a willingness to adhere to intervention protocols will be included.

Exclusion Criteria: Type 1 diabetic patients, pregnancy, having severe comorbidities (cardiovascular, hepatic, or renal failure), or those who are already on intensive lifestyle programs will be excluded.

Sampling Technique: A purposive sampling will be used to recruit eligible participants who satisfy the inclusion criteria.

Data Collection: Baseline demographic information, clinical history, anthropometric measurements, and laboratory tests, including fasting blood glucose, postprandial glucose, HbA1c, lipid profile, and blood pressure, will be collected.

Study Procedure: Subjects will be randomly allocated to either the lifestyle intervention group, which will receive structured diet, exercise, and counseling, or the pharmacological therapy group, which will receive standard anti-diabetic drugs. Follow-up evaluations will be conducted regularly throughout the study period to monitor changes in glycemic and metabolic parameters.

Statistical Analysis: Data will be described and analyzed using inferential and descriptive statistics. Group comparisons will be established with t-tests or ANOVA for continuous data and chi-square tests for categorical data. P-value <0.05 will be taken as statistically significant.

Results

Table 1 shows that the lifestyle intervention group demonstrated greater improvement in glycemic control, with a larger reduction in both HbA1c (1.8% vs. 1.2%) and fasting blood glucose (35 mg/dL vs. 25 mg/dL) compared to the pharmacological therapy group. This suggests that lifestyle modifications have a more substantial impact on improving insulin sensitivity and glucose regulation. Overall, structured lifestyle changes appear more effective than drug therapy alone in optimizing glycemic outcomes in T2DM patients.

Table 1: Glycemic Control Parameters

Parameter	Lifestyle Intervention	Pharmacological Therapy
HbA1c Reduction (%)	1.8	1.2
Fasting Blood Glucose Reduction (mg/dl)	35	25

Figure 1 demonstrates that lifestyle intervention resulted in significantly larger body weight reductions (4.5 kg) compared to pharmacological treatment (1.0 kg). This reflects the pivotal role of organized lifestyle modifications in controlling body weight in T2DM patients.



Figure 1: Weight Loss in T2DM Patients

Table 2 shows that the lifestyle intervention resulted in significantly greater weight loss (4.5 kg) and a decrease in BMI (1.6 kg/m²) than pharmacological treatment (1.0 kg and 0.4 kg/m², respectively). These observations suggest that lifestyle changes are more effective in treating obesity-related aspects of type 2 diabetes mellitus (T2DM). Through improvements in weight and BMI, lifestyle changes are directly responsible for enhanced insulin sensitivity and improved overall metabolic control.

Table 2: Weight and BMI Changes

Parameter	Lifestyle Intervention	Pharmacological Therapy
Weight Loss (kg)	4.5	1.0
BMI Reduction (kg/m²)	1.6	0.4

Figure 2 shows that lifestyle therapy was more effective in achieving a greater decrease in HbA1c (1.8%) compared to pharmacological treatment (1.2%). This indicates that lifestyle modification is more effective for improving long-term glycemic control among T2DM patients.



Figure 2: HbAC1 Reduction in T2DM Patients

Table 3 demonstrates that lifestyle treatment resulted in more significant improvements in lipid profile than pharmacotherapy. Total cholesterol and LDL were lowered more significantly, whereas HDL rose nearly twice as much. Triglyceride lowering was even more significant with lifestyle intervention, which underscores the efficacy of lifestyle modification in overall cardiovascular risk management.

Table 3: Lipid Profile Improvements

Parameter	Lifestyle Intervention	Pharmacological Therapy
Total Cholesterol Reduction (mg/dl)	18	10
LDL Reduction (mg/dl)	12	7
HDL Increase (mg/dl)	4	2
Triglycerides Reduction (mg/dl)	20	12

Discussion

The research demonstrates that lifestyle interventions are more effective than pharmacological therapy in improving lipid profiles in patients with type 2 diabetes mellitus (T2DM). Notably, decreases in total cholesterol (18 mg/dl to 10 mg/dl), low-density lipoprotein (LDL) cholesterol (12 mg/dl to 7 mg/dl), and triglycerides (20 mg/dl to 12 mg/dl) and an increase in high-density lipoprotein (HDL) cholesterol (4 mg/dl to 2 mg/dl) were greater in the lifestyle intervention group.

These results are consistent with earlier research highlighting the effectiveness of lifestyle interventions in improving lipid profiles in patients with type 2 diabetes mellitus (T2DM). For example, one study showed that a formal lifestyle intervention resulted in significant increases in fasting blood glucose and lipid profiles following one year [10]. Similarly, the study of the Diabetes Prevention Program (DPP) demonstrated that lifestyle interventions resulted in greater decreases in LDL cholesterol and triglycerides compared to drug therapy [11]. In addition, a meta-analysis revealed that lifestyle interventions reduced the incidence of T2DM by 25% and lowered levels of total cholesterol and triglycerides [12].

The more favorable lipid profile changes observed with lifestyle interventions may be attributed to their multifaceted approach, which involves a combination of diet, exercise, and behavioral modification. These factors address the core study by targeting the pathophysiology of T2DM, increasing insulin sensitivity, inducing weight loss, and enhancing endothelial function. Complication-wise, they are more holistic in addressing the lipid aspect, while pharmacological treatments are mainly focused on glucose control and may have a lesser impact on lipid metabolism [13].

In addition to the benefits of a lipid profile, lifestyle interventions offer long-term advantages. They have been linked to decreases in body weight, blood pressure, and the need for pharmacological treatment, as well as improvements in quality of life. To illustrate, the study found that intensive lifestyle interventions were associated with substantial weight loss and decreases in HbA1c levels, with numerous individuals reducing or discontinuing their diabetes medications [14].

Ultimately, the evidence supports the use of lifestyle interventions as a cornerstone in the treatment of type 2 diabetes mellitus (T2DM), particularly for improving lipid profiles and reducing cardiovascular risk. Though pharmacological therapies will continue to play a central role in glucose control, the addition of lifestyle changes could provide a more salient strategy for T2DM management and its resultant metabolic complications.

Conclusion

This research concludes that lifestyle interventions are superior to pharmacologic treatment for improving glycemic control, body weight, BMI, and lipid profiles in type 2 diabetic patients. Systematic lifestyle modifications, including diet, exercise, and counseling, as well as reducing blood glucose levels, also improve overall metabolic status by lowering total cholesterol, LDL, and triglycerides, while raising HDL. These results are in agreement with earlier research that noted the long-term advantages of lifestyle changes. Hence, the inclusion of lifestyle interventions in addition to pharmacotherapy presents a holistic approach to maximize metabolic benefits and lower cardiovascular risk in T2DM patients.

Limitations

The investigation was also limited by its single-center design and relatively short follow-up duration of one year, which may not accurately reflect the long-term effects of the interventions. The sample size was small, and compliance with lifestyle protocols was based on self-report, which carries the potential for bias. Types and doses of medication were also variable and may have impacted comparative results.

Recommendations

Future research should involve multicenter trials with larger sample sizes and more extended follow-up periods to determine the sustained benefits. An

objective assessment of lifestyle adherence is recommended. The combination of pharmacotherapy and intensive lifestyle programs may maximize outcomes. Individualized interventions tailored to patient preferences, comorbidities, and socioeconomic status should be prioritized to enhance compliance and effectiveness.

References

1. de Hoogh, Iris M., et al. The effect of a lifestyle intervention on type 2 diabetes pathophysiology and remission: the stevenshof pilot study. Nutrients 13.7 (2021): 2193.
2. Rein, Michal, et al. Effects of personalized diets by prediction of glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized dietary intervention pilot trial. BMC medicine 20.1 (2022): 56.
3. Shah, Sayed ZA, et al. Movement is improvement: the therapeutic effects of exercise and general physical activity on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Therapy 12.3 (2021): 707-732.
4. Garcia-Molina, Laura, et al. Improving type 2 diabetes mellitus glycaemic control through lifestyle modification implementing diet intervention: a systematic review and meta-analysis. European journal of nutrition 59.4 (2020): 1313-1328.
5. Megahed, Fatma Ibrahim Abdel-Latif. Effect of Lifestyle Modification on Glycemic Control of Type 2. Psychology and Pathophysiological Outcomes of Eating (2021): 185.
6. Pousinho, Sarah, et al. Clinical pharmacists interventions in the management of type 2 diabetes mellitus: a systematic review. Pharmacy Practice (Granada) 18.3 (2020).
7. Biancalana, Edoardo, et al. Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study. Acta diabetologica 58.4 (2021): 431-436.
8. Dwibedi, Chinmay, et al. Effect of self-managed lifestyle treatment on glycemic control in patients with type 2 diabetes. NPJ Digital Medicine 5.1 (2022): 60.
9. Biamonte, Emilia, et al. Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect. Endocrine 72.3 (2021): 604-610.
10. Pani, Arianna, et al. From prediabetes to type 2 diabetes mellitus in women with polycystic ovary syndrome: lifestyle and pharmacological management. International Journal of Endocrinology 2020.1 (2020): 6276187.
11. Yefet, Enav, et al. Effects of probiotics on glycemic control and metabolic parameters in gestational diabetes mellitus: systematic review and meta-analysis. Nutrients 15.7 (2023): 1633.
12. Moriconi, Eleonora, et al. Very-low-calorie ketogenic diet as a safe and valuable tool for long-term glycemic management in patients with obesity and type 2 diabetes. Nutrients 13.3 (2021): 758.
13. Zikou, Eva, et al. The effect of probiotic supplements on metabolic parameters of people with type 2 diabetes in Greece—a randomized, double-blind, placebo-controlled study. Nutrients 15.21 (2023): 4663.
14. Giagulli, Vito Angelo, et al. Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism. Andrology 8.3 (2020): 654-662.